Genetic Technologies Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) announced that CEO Simon Morriss will appear on The RedChip Money Report® airing on the Bloomberg Network on May 15, 2021. The interview will cover key updates on the company's lead products, including GeneType for Breast Cancer and GeneType for Colorectal Cancer, as well as the Covid19 Risk Assessment test. Morriss will also discuss future milestones and product commercialization plans, which are critical for investor awareness.
- CEO interview provides visibility to investors, potentially boosting confidence.
- Updates on lead risk assessment products could enhance market interest.
- Pipeline development of risk assessment products shows future growth potential.
- None.
MELBOURNE, Australia, May 13, 2021 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a diversified Genomics and AI driven preventative health business, today announced an interview with Simon Morriss, CEO, will air on The RedChip Money Report® on the Bloomberg Network in the U.S. on Saturday, May 15th, at 7 p.m. local time in 73M homes across the United States.
In the exclusive interview, Mr. Morriss discusses the Company’s upcoming milestones, updates on the company’s lead risk assessment products, GeneType for Breast Cancer, for non-hereditary breast cancer and GeneType for Colorectal Cancer, as well as their Covid19 Risk Assessment test. Mr. Morriss also discusses the company’s developing pipeline of risk assessment products and commercialization plans.
To view the interview segment, please visit: https://youtu.be/-o-2YWJ7FyU
“The RedChip Money Report" delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies.
About Genetic Technologies Limited
Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead products GeneType for Breast Cancer for non-hereditary breast cancer and GeneType for Colorectal Cancer are clinically validated risk assessment tests and are first in class. Genetic Technologies is developing a pipeline of risk assessment products.
For more information, please visit www.gtglabs.com
| Investor Relations (AUS) | Investor Relations and Media (US) |
| Stephanie Ottens | Dave Gentry |
| Market Eye | 1 800 RED CHIP (733 2447) |
| M: +61 434 405 400 | Cell: 407 491 4498 |
| E: stephanie.ottens@marketeye.com.au | E: dave@redchip.com |
FAQ
What date will Simon Morriss appear on The RedChip Money Report?
What products are highlighted in the Genetic Technologies interview?
What network will air the interview with Genetic Technologies' CEO?
How many homes will The RedChip Money Report be available in?
What is the significance of the upcoming milestones discussed in the interview?
